Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 537 participants.
Also called NCT06354660
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 537 participants
- Sponsor
- Registry
-
NCT06354660
-
- Other papers using this trial's data
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, India, Mexico, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT06354660. Randomized; double masking; primary purpose treatment. Start 2024-04-10 (actual); primary completion 2026-01-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
- Condition
- Diabetes Type 2
- Intervention (Drug)
- Retatrutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06354660- Content hash
54cd037a367ca3f9ce347ef0161817078c8dbe7beb771f2b69f94205d6249a7e